

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Complete Listing of Claims:

1. (Currently amended) A method for the treatment ~~and/or prevention~~ of a Parkinsonism-Plus Syndrome comprising administering to a person ~~in need thereof~~ **with Parkinsonism-Plus Syndrome an effective amount of a** substance selected from the group consisting of:

- (a) human growth hormone;
- (b) a variant of (a) which has at least 70% sequence identity thereto and which has agonistic activity on the hGH receptor;
- ~~(c) a variant of (a) having agonistic activity on the hGH receptor and which is encoded by a DNA sequence which hybridizes to the complement of the native DNA sequence encoding (a);~~
- (d) a salt of ~~(a), (b) or (c)~~ **any of (a) to (b)**;
- (e) human growth hormone releasing hormone (hGHRH);
- (f) a variant of (e) which has at least ~~[[70%]]~~ **95%** sequence identity thereto and which has agonistic activity on the hGHRH receptor;
- ~~(g) a variant of (e) having agonistic activity on the hGHRH receptor and which is encoded by a DNA sequence which hybridizes to the complement of the native DNA sequence encoding (e) under moderately stringent conditions;~~
- (h) a salt of ~~(e), (f) or (g)~~ **any of (e) to (f)**; and

(i) combinations thereof.

2. (Previously presented) The method of claim 1, wherein the Parkinsonism-Plus Syndrome is selected from the group consisting of Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Parkinson's-amyotrophic lateral sclerosis-dementia of Guam, Generalized Lewy body disease, Corticobasal ganglionic degeneration, Alzheimer's/Parkinson's overlap syndrome, Huntington's disease: rigid variant, Hallervorden-Spatz disease, and Gerstmann-Strausler syndrome.

3. (Canceled).

4. (Canceled).

5. (Previously presented) The method of claim 1, wherein the substance is a naturally-occurring human growth hormone.

6. (Previously presented) The method of claim 1, wherein the substance is recombinant human growth hormone.

7. (Canceled).

8. (Previously presented) The method of claim 1, wherein the variant comprises amino acids 177 to 191 of hGH.

9. (Previously presented) The method of claim 1, wherein the variant is methionyl human growth hormone.

10. (Previously presented) The method of claim 1, wherein the variant is lacking the 15 amino acid residues from Glu32 to Glu46 of hGH.

11. (Currently amended) The method of claim 1, wherein the variant is lacking the first eight amino acid residues at the N-terminus **of hGH**.

12. (Currently amended) The method of claim 1, wherein the variant is lacking the first 13 amino acid residues at the N-terminus **of hGH**.

13. (Previously presented) The method of claim 1, wherein the substance comprises a dimer of human growth hormone selected from the group consisting of a disulfide dimer connected through interchain disulfide bonds, a covalent irreversible non-disulfide dimer, a non-covalent dimer, and mixtures thereof.

14. (Previously presented) The method of claim 1, wherein the substance is chemically derivatized.

15. (Previously presented) The method of claim 14, wherein the derivative is selected from the group consisting of:

- (a) the substance is acetylated at the N-terminus;
- (b) the substance is deaminated;
- (c) the substance is sulfoxidized at one or more methionine residues; and
- (d) the substance is derivatized at one or more amino acid side chains with a polyethylene glycol (PEG) moiety.

16. (Canceled).

17. (Canceled).

18. (Previously presented) The method of claim 1, wherein the substance is administered at a dosage selected from the group consisting of:

- (a) about 0.1 to 10 mg per person per day;
- (b) about 0.5 to 6 mg per person per day;

- (c) about 1 mg per person per day;
- (d) a dosage administered daily;
- (e) a dosage administered every other day;
- (f) alternating daily dosages, wherein the first dosage is higher than the second dosage;
- (g) alternating daily dosages, wherein the first dosage is about 1 mg per person and the second dosage is about 0.5 mg per person;
- (h) about 6 mg per person;
- (i) about 5 mg per person; and
- (j) about 4.5 mg per person.

19. (Canceled).

20. (Canceled).

21. (Canceled).

22. (Canceled).

23. (Canceled).

24. (Canceled).

25. (Previously Presented) The method of claim 14, wherein the substance is derivatized at one or more side chains of amino acid residues.

26. (Canceled).

27. (Canceled).

28. (Withdrawn) The method of claim 1, wherein the IGF is IGF-I or IGF-II.

29. (Withdrawn) The method of claim 1, wherein the substance is IGF and the patient is further administered IGFBP (Insulin-like Growth Factor Binding Protein), simultaneous, sequential, or separate from the IGF.

30. (Withdrawn) The method of claim 29, wherein the IGFBP is IGFBP3.

31. (Canceled).

32. (Canceled).

33. (Previously presented) The method of claim 1, wherein the substance is administered in a manner selected from the group consisting of:

- (a) the substance is administered subcutaneously;
- (b) the substance is administered intramuscularly; and
- (c) the substance is administered with an auto-injector.

34. (Canceled).

35. (Canceled).

36. (Withdrawn) The method of claim 1 wherein the nucleic acid is an expression vector.

37. (Withdrawn) A method for the treatment and/or prevention of a Parkinsonism-Plus Syndrome, comprising administering to a person in need thereof a cell, wherein the cell produces a substance capable of treating or preventing a Parkinsonism-Plus Syndrome according to the method of claim 1.

38. (Canceled)